Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
BHBiohaven Ltd. logo

Biohaven Ltd. (BHVN)

New York Stock Exchange · Currency in USD
$13.88 ▼ -0.81 (-5.51%)
At close: Oct 23, 4:00 PM ET. Market closed.
$13.83 ▼ -0.05 (-0.34%)
After hours: Oct 23, 7:58 PM ET

Summary

Previous Close
$14.69
Open
$15.22
Day's Range
$13.83 – $15.30
52 Week Range
$7.48 – $18.57
Volume
4,690,019
Avg. Volume
3,155,868
Market Cap
$2.10B
Beta (5Y Monthly)
3.20
PE Ratio (TTM)
--
EPS (TTM)
-$3.90
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$24.67

Profile: Biohaven Ltd.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
274
CEO
Vladimir Coric

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$0.78 · Revenue est. $70.00M
DateEst.Actual
Aug 10, 2026-$0.76-$0.91Miss
May 4, 2026-$0.86-$0.88Miss
Mar 2, 2026-$1.22-$1.21Beat
Nov 10, 2025-$1.91-$1.64Beat
Aug 11, 2025-$1.94-$1.94Beat
May 12, 2025-$1.67-$2.17Miss

Analyst view

Consensus price target
$24.67 ▲ +77.7%
Range $11.00 – $48.00
Rating: Buy
Buy 64% · Hold 32% · Sell 4%

Get free alerts on BHVN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.